These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23298809)

  • 41. Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme.
    Fabian L; Taverna Porro M; Gómez N; Salvatori M; Turk G; Estrin D; Moglioni A
    Eur J Med Chem; 2020 Feb; 188():111987. PubMed ID: 31893549
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
    Chen X; Ding L; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Eur J Med Chem; 2020 Sep; 202():112549. PubMed ID: 32712537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recent Advances in the Design and Development of Non-nucleoside Reverse Transcriptase Inhibitor Scaffolds.
    Shirvani P; Fassihi A; Saghaie L
    ChemMedChem; 2019 Jan; 14(1):52-77. PubMed ID: 30417561
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography.
    Chan AH; Lee WG; Spasov KA; Cisneros JA; Kudalkar SN; Petrova ZO; Buckingham AB; Anderson KS; Jorgensen WL
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9725-9730. PubMed ID: 28827354
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus.
    Mao C; Sudbeck EA; Venkatachalam TK; Uckun FM
    Antivir Chem Chemother; 1999 Sep; 10(5):233-40. PubMed ID: 10574178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
    Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers M; Van Aken KJ; Arnold E; Das K; Kilonda A; Hoornaert GJ; Compernolle F; Cegla M; Azzam RA; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Janssen PA
    J Med Chem; 2005 Mar; 48(6):1910-8. PubMed ID: 15771435
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Liu N; Qin B; Sun LQ; Yu F; Lu L; Jiang S; Lee KH; Xie L
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3719-23. PubMed ID: 25042339
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
    Li A; Ouyang Y; Wang Z; Cao Y; Liu X; Ran L; Li C; Li L; Zhang L; Qiao K; Xu W; Huang Y; Zhang Z; Tian C; Liu Z; Jiang S; Shao Y; Du Y; Ma L; Wang X; Liu J
    J Med Chem; 2013 May; 56(9):3593-608. PubMed ID: 23540737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations.
    Zeevaart JG; Wang L; Thakur VV; Leung CS; Tirado-Rives J; Bailey CM; Domaoal RA; Anderson KS; Jorgensen WL
    J Am Chem Soc; 2008 Jul; 130(29):9492-9. PubMed ID: 18588301
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exploring the dNTP -binding site of HIV-1 reverse transcriptase for inhibitor design.
    Gu W; Martinez S; Singh AK; Nguyen H; Rozenski J; Schols D; Herdewijn P; Das K; De Jonghe S
    Eur J Med Chem; 2021 Dec; 225():113785. PubMed ID: 34425311
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Stanton RA; Lu X; Detorio M; Montero C; Hammond ET; Ehteshami M; Domaoal RA; Nettles JH; Feraud M; Schinazi RF
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4101-5. PubMed ID: 27390064
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Cichero E; Fossa P
    J Mol Model; 2012 Apr; 18(4):1573-82. PubMed ID: 21805124
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
    Wu B; Kuhen K; Ngoc Nguyen T; Ellis D; Anaclerio B; He X; Yang K; Karanewsky D; Yin H; Wolff K; Bieza K; Caldwell J; He Y
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3430-3. PubMed ID: 16632349
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and anti-HIV activity of 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors.
    Arranz ME; Díaz JA; Ingate ST; Witvrouw M; Pannecouque C; Balzarini J; De Clercq E; Vega S
    Bioorg Med Chem; 1999 Dec; 7(12):2811-22. PubMed ID: 10658585
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
    Meng G; Liu Y; Zheng A; Chen F; Chen W; De Clercq E; Pannecouque C; Balzarini J
    Eur J Med Chem; 2014 Jul; 82():600-11. PubMed ID: 24952305
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
    Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
    J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group.
    Lee WG; Gallardo-Macias R; Frey KM; Spasov KA; Bollini M; Anderson KS; Jorgensen WL
    J Am Chem Soc; 2013 Nov; 135(44):16705-13. PubMed ID: 24151856
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of a 3-aminoimidazo[1,2-a]pyridine inhibitor of HIV-1 reverse transcriptase.
    Elleder D; Baiga TJ; Russell RL; Naughton JA; Hughes SH; Noel JP; Young JA
    Virol J; 2012 Dec; 9():305. PubMed ID: 23231773
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors.
    Santos LH; Ferreira RS; Caffarena ER
    Mem Inst Oswaldo Cruz; 2015 Nov; 110(7):847-64. PubMed ID: 26560977
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Wu HQ; Yao J; He QQ; Chen WX; Chen FE; Pannecouque C; De Clercq E; Daelemans D
    Bioorg Med Chem; 2015 Feb; 23(3):624-31. PubMed ID: 25537532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.